Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands.
Semin Thromb Hemost. 2009 Sep;35(6):554-9. doi: 10.1055/s-0029-1241048. Epub 2009 Sep 28.
Atrial fibrillation (AF) is the most common sustained arrhythmia of the Western world. The increased ischemic stroke risk of the AF patient is one of the most important clinical issues to manage. Despite the well-known benefit of oral anticoagulation in high-risk AF patients, these drugs are widely underused in daily practice all over the world. We describe old and new paradigms of the use of oral anticoagulation. In the future, increased comprehensibility of stroke risk scores, development of a validated clinical bleed risk score, and new patient and physician user-friendly antithrombotic medication may contribute to improved adequate use of oral anticoagulation in AF patients.
心房颤动(AF)是西方世界最常见的持续性心律失常。AF 患者缺血性卒中风险增加是最重要的临床管理问题之一。尽管口服抗凝剂在高危 AF 患者中具有明显益处,但这些药物在全球范围内的日常实践中广泛未被充分使用。我们描述了口服抗凝剂使用的旧和新范式。在未来,增加中风风险评分的可理解性、开发经过验证的临床出血风险评分,以及新的患者和医生友好型抗血栓药物,可能有助于改善 AF 患者口服抗凝剂的充分使用。